Clinical trial · Observational
MRI Optimization Study in Stage III NSCLC
MRI for Radiotherapy Treatment Planning of Stage III NSCLC: an MRI Optimization Study in Healthy Volunteers and Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Radiation therapy uses radiation to treat lung tumors and metastases in the mediastinum. In order to irradiate as precise as possible, and in order to evaluate the effect of radiation treatment, it is important to depict the lung tumor and the lymph node metastases as accurate as possible. Currently, radiation oncologists use PET-CT for this purpose. However, PET-CT does have its drawbacks, and partly because of this, large volumes are irradiated in current treatment. The investigators believe that MRI can be used to improve depiction of the tumor and lymph nodes and of their motion. However, there is currently no MRI protocol available which is aimed at improving radiotherapy. In this study, the investigators want to select the optimal MRI settings for depiction of the lung tumor, the lymph node metastases and their movement. The investigators plan to do this by first examining 10 healthy volunteers, followed by 20 patients with non-small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Stage III Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 1 MRI scan | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Healthy volunteers 1 MRI scan
- description
- Healthy volunteers, recruited at the UMC Utrecht, older than 18, who do not meet the exclusion criteria of the department of Radiology. Healthy volunteers will receive 1 MRI scan without contrast agent.
- interventionNames
- Other: 1 MRI scan
- label
- Patients with stage III NSCLC, 1 MRI scan
- description
- Patients with histopathologically or cytologically proven stage III NSCLC (excluding T4N0), older than 18, with a recent (≤ 21 days) GFR value available Patients will receive 1 MRI scan with contrast agent.
- interventionNames
- Other: 1 MRI scan
Primary outcomes (1)
- measure
- Optimization and validation of an MRI scanning protocol
- timeFrame
- Healthy volunteers: 1 time point, patients: at start of radiation treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Healthy volunteers 1. ≥18 years. 2. Written informed consent * Patients 1. Patients with histopathologically or cytologically proven stage III NSCLC (excluding T4N0) referred to the department of Radiation Oncology 2. ≥ 18 years. 3. Written informed consent. 4. Recent (≤ 21 days) GFR value available Exclusion Criteria: * Healthy volunteers: 1\. Volunteers who meet exclusion criteria for MRI following the protocol of the department of Radiology of the UMC Utrecht * Patients: 1. Patients who meet exclusion criteria for MRI following the protocol of the department of Radiology of the UMC Utrecht. 2. Patients for whom lying still in a supine position for 45 minutes is physically too strenuous (e.g. due to orthopnea). 3. Glomerular Filtration Rate (GFR) of \<30 mL/min/1.73m2 (UMCU protocol 'MRI Contra-indicaties', Version 3 January 2013). 4. Patients with nephrogenic systemic fibrosis, nephrogenic fibrosing dermopathy or severe renal insufficiency (UMCU protocol 'MRI Contra-indicaties', Version 3 January 2013).
References
Publications (0)
Data not yet available